Illumina Inc. (ILMN) shares plummeted 5.16% in the pre-market session on Monday, following a series of negative developments that have cast doubts over the biotechnology company's prospects.
The stock selloff comes after Barclays downgraded the company to "Underweight" from "Equal-Weight," citing concerns over revenue declines and increasing competition in the market. Similarly, Morgan Stanley maintained a "Hold" rating on ILMN, setting a price target of $136.
Compounding the woes, Illumina has found itself embroiled in geopolitical tensions with China. According to reports, the company was added to China's unreliable entity list for allegedly breaching fair market rules by cutting ties with Chinese firms following US tariffs imposed during the Trump administration. Illumina has stated that it is in discussions with Chinese authorities to seek solutions to this issue.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。